Fitusiran

Drug Profile

Fitusiran

Alternative Names: ALN AT3; ALN-AT3SC; SAR 439774

Latest Information Update: 25 Jan 2017

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Antifibrinolytics; Antihaemorrhagics; Antisense RNA; Drug conjugates; Small interfering RNA
  • Mechanism of Action Antithrombin III inhibitors; Haemostasis stimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A; Haemophilia B
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Haemophilia A; Haemophilia B

Most Recent Events

  • 16 Dec 2016 Alnylam Pharmaceuticals intends to initiate the ATLAS-A/B phase III trial in severe haemophilia A and B
  • 16 Dec 2016 Alnylam Pharmaceuticals intends to initiate the ATLAS-INH phase III trial in severe haemophilia A and B
  • 16 Dec 2016 Alnylam Pharmaceuticals intends to initiate the ATLAS-PPX phase III trial in severe haemophilia A and B
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top